Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

@article{Lauffenburger2014MedicationUA,
  title={Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.},
  author={Julie C Lauffenburger and Christina L. Mayer and Roy L. Hawke and Kim L R Brouwer and Michael W. Fried and Joel F. Farley},
  journal={European journal of gastroenterology & hepatology},
  year={2014},
  volume={26 10},
  pages={1073-82}
}
BACKGROUND With the advent of the direct-acting antiviral agents, significant drug-drug interaction (DDI) potential now exists for patients treated for chronic hepatitis C virus (HCV) infection. However, little is known about how often patients with HCV infection use medications that may interact with newer HCV treatments, especially those with cytochrome P450 3A (CYP3A) DDI potential. METHODS Using a large US commercial insurance database, medication use and comorbidity burden were examined… CONTINUE READING